Biogen Inc. stock price
Today's NASDAQ:BIIB chart, history & news
Price:
259.00
USD
Change:
-10.85 (-4.02%)
Key stats
| Price open | |
|---|---|
| Previous close | 269.85 |
| Market cap | 39.45B |
| Volume | 2.36M |
| Day high | |
| Day low | |
| Year high | 363.92 |
| Year low | 223.25 |
| Year to date change | 6.18% |
| P/E ratio | 10.44 |
Company Profile
Fundamentals
Insider Information
News
About Biogen Inc.
At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
Company information
Company name
Biogen Inc.
Exchange
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
Employees
7,300
CEO
George Scangos
Address
225 Binney St, Cambridge, Massachusetts, 02142-1031
Country
United States
Contact information
17814642000
Website
https://www.biogen.com/
Latest Biogen Inc. news
Biogen Inc. earnings reports (2020)
| Q3 2020 | Q2 2020 | Q1 2020 | Q1 2020 | |
|---|---|---|---|---|
| Actual EPS | 8.84 | 10.26 | 9.14 | 9.14 |
| Consensus EPS | 8.09 | 8.02 | 7.72 | 7.72 |
| Announce Time | BTO | BTO | BTO | BTO |
| Number of Estimates | 29 | 27 | 27 | 27 |
| EPS Surprise Dollar | 0.75 | 2.24 | 1.42 | 1.42 |
| EPS Report Date | 21-10-2020 | 22-07-2020 | 21-04-2020 | 21-04-2020 |
| Fiscal End Date | 30-09-2020 | 30-06-2020 | 30-03-2020 | 30-03-2020 |
| Year Ago | 9.17 | 9.15 | 6.98 | 6.98 |
| Year Ago % Change | -3.6% | 12.13% | 30.95% | 30.95% |
Biogen Inc. earnings reports (2019)
| Q4 2019 | Q3 2019 | Q2 2019 | |
|---|---|---|---|
| Actual EPS | 8.34 | 9.17 | 9.15 |
| Consensus EPS | 8.03 | 8.3 | 7.53 |
| Announce Time | BTO | BTO | BTO |
| Number of Estimates | 28 | 24 | 27 |
| EPS Surprise Dollar | 0.31 | 0.87 | 1.62 |
| EPS Report Date | 30-01-2020 | 21-10-2019 | 22-07-2019 |
| Fiscal End Date | 31-12-2019 | 29-09-2019 | 29-06-2019 |
| Year Ago | 6.99 | 7.4 | 5.8 |
| Year Ago % Change | 19.31% | 23.92% | 57.76% |
Biogen Inc. income statements (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Total Revenue | 3.38B | 3.12B | 3.40B | 3.16B | 3.16B |
| Cost of Revenue | 449.10M | 563.90M | 523.90M | 561.20M | 561.20M |
| Gross Profit | 2.93B | 2.56B | 2.88B | 2.60B | 2.60B |
| Research & Development | 1.14B | 1.09B | 596.30M | 427.90M | 427.90M |
| Selling General & Admin | 573.10M | 573.10M | 541.10M | 570.10M | 570.10M |
| Operating Expense | 2.32B | 2.23B | 1.66B | 1.56B | 1.56B |
| Operating Income | 1.06B | 892.50M | 1.74B | 1.60B | 1.60B |
| Other Income Expense Net | 0 | 65.30M | 296.80M | 101.90M | 101.90M |
| EBIT | 1.04B | 892.50M | 1.74B | 1.60B | 1.60B |
| Interest Income | 50.30M | 56.30M | 56.60M | 44.30M | 44.30M |
| Pretax Income | 0.94B | 0.96B | 2.04B | 1.70B | 1.70B |
| Income Tax | 240.80M | 240.80M | 446.10M | 292M | 292M |
| Minority Interest | 2.40M | 2.40M | 64.40M | -6.5M | -6.5M |
| Net Income | 701.50M | 701.50M | 1.54B | 1.40B | 1.40B |
| Net Income Basic | 701.50M | 701.50M | 1.54B | 1.40B | 1.40B |
Biogen Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 3.26B | 3.17B | 3.21B | 3.08B |
| Cost of Revenue | 560M | 498M | 546.40M | 670.20M |
| Gross Profit | 2.70B | 2.67B | 2.66B | 2.41B |
| Research & Development | 646.50M | 540.40M | 484.80M | 563.70M |
| Selling General & Admin | 664.90M | 554.50M | 587.60M | 567.70M |
| Operating Expense | 1.87B | 1.59B | 1.62B | 1.80B |
| Operating Income | 1.39B | 1.58B | 1.59B | 1.28B |
| Other Income Expense Net | 343.20M | 201M | 171.30M | 581.10M |
| EBIT | 1.39B | 1.58B | 1.59B | 1.28B |
| Interest Income | 46M | 45.80M | 47.70M | 47.90M |
| Pretax Income | 1.73B | 1.78B | 1.76B | 1.86B |
| Income Tax | 276.10M | 211.30M | 248.10M | 422.50M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 1.44B | 1.55B | 1.49B | 1.41B |
| Net Income Basic | 1.44B | 1.55B | 1.49B | 1.41B |
Biogen Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 3.15B | 3.09B | 3B | 2.82B |
| Cost of Revenue | 565.80M | 553.40M | 528.40M | 549.90M |
| Gross Profit | 2.58B | 2.54B | 2.47B | 2.27B |
| Research & Development | 611.60M | 507.90M | 0.98B | 496.70M |
| Selling General & Admin | 580.20M | 497.70M | 516.20M | 501.30M |
| Operating Expense | 1.76B | 1.56B | 2.03B | 1.55B |
| Operating Income | 1.39B | 1.53B | 0.97B | 1.27B |
| Other Income Expense Net | 23.80M | 282.60M | 204.30M | 226.30M |
| EBIT | 1.39B | 1.53B | 0.97B | 1.27B |
| Interest Income | 49.40M | 49M | 51.70M | 50.50M |
| Pretax Income | 1.41B | 1.81B | 1.18B | 1.49B |
| Income Tax | 469.60M | 369.80M | 263.70M | 322.50M |
| Minority Interest | -1.9M | -1.5M | 48.40M | -1.7M |
| Net Income | 0.95B | 1.44B | 866.60M | 1.17B |
| Net Income Basic | 0.95B | 1.44B | 866.60M | 1.17B |
Biogen Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 3B | 2.77B | 2.73B |
| Cost of Revenue | 617.80M | 478.90M | 483.70M |
| Gross Profit | 2.39B | 2.29B | 2.24B |
| Research & Development | 587.60M | 446.40M | 796.20M |
| Selling General & Admin | 553.90M | 433.80M | 430.20M |
| Operating Expense | 1.76B | 1.36B | 1.71B |
| Operating Income | 1.24B | 1.41B | 1.02B |
| Other Income Expense Net | 155M | 197.50M | 114.60M |
| EBIT | 1.24B | 1.41B | 1.02B |
| Interest Income | 56.80M | 61.80M | 63.60M |
| Pretax Income | 1.40B | 1.61B | 1.13B |
| Income Tax | 1.57B | 383.80M | 269.60M |
| Minority Interest | 131.10M | 0 | 0 |
| Net Income | -297.4M | 1.23B | 862.80M |
| Net Income Basic | -297.4M | 1.23B | 862.80M |
Biogen Inc. balance sheet (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Current Cash | 3.58B | 2.22B | 2.38B | 2.59B | 2.59B |
| Receivables | 2.55B | 2.55B | 2.57B | 2.60B | 2.60B |
| Inventory | 1.03B | 1.03B | 0.95B | 858.80M | 858.80M |
| Current Assets | 7.84B | 7.84B | 8.49B | 8.01B | 8.01B |
| Other Current Assets | 683.50M | 683.50M | 638.80M | 683.80M | 683.80M |
| Short Term Investments | 683.50M | 1.36B | 1.94B | 1.27B | 1.27B |
| Long Term Investments | 17.09B | 2.50B | 2.29B | 1.84B | 1.84B |
| Property/Plant Equipment | 3.36B | 3.79B | 3.77B | 3.70B | 3.70B |
| Good Will | N.A | N.A | N.A | N.A | N.A |
| Intangible Assets | 3.32B | 3.32B | 3.38B | 3.45B | 3.45B |
| Tangible Assets (Net) | 1.68B | -9.15B | -8.59B | -7.36B | -7.36B |
| Other Assets | 1.83B | 349.70M | 116.90M | 263.10M | 263.10M |
| Total Assets | 24.93B | 24.93B | 25.51B | 26.12B | 26.12B |
| Accounts Payable | 398.40M | 398.40M | 383.90M | 389M | 389M |
| Other Current Liabilities | 3.41B | 3.29B | 2.49B | 2.44B | 2.44B |
| Total Current Liabilities | 3.80B | 3.80B | 3.45B | 4.64B | 4.64B |
| Total Liabilities | 14.18B | 14.19B | 14.22B | 13.58B | 13.58B |
| Long Term Debt | 7.43B | 7.83B | 7.84B | 4.86B | 4.86B |
| Current Long Term Debt | 0 | N.A | N.A | 1.50B | 1.50B |
| Minority Interest | -14M | 2.40M | 64.40M | -6.5M | -6.5M |
| Common Stock | 100K | 153.90M | 158.30M | 167.30M | 167.30M |
| Treasury Stock | -2.98B | 2.98B | 2.98B | 2.98B | 2.98B |
| Retained Earnings | 13.96B | 13.96B | 14.47B | 15.67B | 15.67B |
| Capital Surplus | N.A | N.A | N.A | 100K | 100K |
| Shareholder Equity | 10.76B | 10.76B | 11.31B | 12.55B | 12.55B |
| Other Liabilities | N.A | N.A | N.A | N.A | N.A |
Biogen Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 2.91B | 2.34B | 1.72B | 2.24B |
| Receivables | 2.47B | 2.52B | 2.52B | 2.62B |
| Inventory | 804.20M | 751.80M | 776.70M | 770.20M |
| Current Assets | 8.38B | 8.45B | 7.91B | 8.94B |
| Other Current Assets | 631M | 743.20M | 1.66B | 1.65B |
| Short Term Investments | 1.56B | 2.09B | 1.23B | 1.67B |
| Long Term Investments | 2.38B | 2.22B | 1.66B | 2.33B |
| Property/Plant Equipment | 3.67B | 3.56B | 3.51B | 3.46B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 3.53B | 3.39B | 3.68B | 3.06B |
| Tangible Assets (Net) | -6.58B | -5.7B | -6.97B | -5.18B |
| Other Assets | 278.70M | 836.80M | 0.96B | 0.94B |
| Total Assets | 27.23B | 27.48B | 26.29B | 26.45B |
| Accounts Payable | 530.80M | 382.20M | 377.10M | 378M |
| Other Current Liabilities | 2.69B | 2.36B | 2.41B | 2.53B |
| Total Current Liabilities | 4.86B | 4.43B | 3.21B | 3.15B |
| Total Liabilities | 13.90B | 13.49B | 13.34B | 12.62B |
| Long Term Debt | 4.87B | 4.87B | 6.37B | 6.38B |
| Current Long Term Debt | 1.50B | 1.50B | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 174.20M | 181.90M | 184.80M | 195.20M |
| Treasury Stock | 2.98B | 2.98B | 2.98B | 2.98B |
| Retained Earnings | 16.46B | 17.07B | 16.18B | 17.03B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 13.34B | 14B | 12.95B | 13.83B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Biogen Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 1.22B | 2.39B | 1.25B | 4.11B |
| Receivables | 2.49B | 2.53B | 2.43B | 2.49B |
| Inventory | 0.93B | 0.92B | 0.93B | 890.80M |
| Current Assets | 7.64B | 8.72B | 7.43B | 10.20B |
| Other Current Assets | 687.60M | 848.30M | 843.30M | 895.90M |
| Short Term Investments | 2.31B | 2.04B | 1.97B | 1.81B |
| Long Term Investments | 2.73B | 1.93B | 1.71B | 1.28B |
| Property/Plant Equipment | 3.60B | 3.54B | 3.41B | 3.33B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 3.12B | 3.38B | 3.66B | 3.79B |
| Tangible Assets (Net) | -6.1B | -5.18B | -6.34B | -4.05B |
| Other Assets | 333.70M | 322M | 353.10M | 298.50M |
| Total Assets | 25.29B | 25.49B | 23.95B | 26.09B |
| Accounts Payable | 370.50M | 342.30M | 295.70M | 345.80M |
| Other Current Liabilities | 2.86B | 2.58B | 2.63B | 2.57B |
| Total Current Liabilities | 3.30B | 3.17B | 3.15B | 3.15B |
| Total Liabilities | 12.26B | 11.73B | 11.70B | 12.05B |
| Long Term Debt | 5.94B | 5.93B | 5.93B | 5.93B |
| Current Long Term Debt | N.A | N.A | N.A | 3.30M |
| Minority Interest | -1.9M | -1.5M | 48.40M | -1.7M |
| Common Stock | 197.20M | 201.48M | 201.44M | 211.01M |
| Treasury Stock | 2.98B | 2.98B | 2.98B | 2.98B |
| Retained Earnings | 16.26B | 16.94B | 15.50B | 17.33B |
| Capital Surplus | N.A | 47.80M | N.A | N.A |
| Shareholder Equity | 13.04B | 13.77B | 12.26B | 14.05B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Biogen Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 1.57B | 1.55B | 1.17B |
| Receivables | 2.32B | 2.09B | 2.13B |
| Inventory | 0.90B | 1.01B | 0.94B |
| Current Assets | 7.87B | 7.57B | 7.11B |
| Other Current Assets | 0.96B | 0.97B | 1.15B |
| Short Term Investments | 2.12B | 1.96B | 1.72B |
| Long Term Investments | 3.14B | 3.15B | 2.73B |
| Property/Plant Equipment | 3.18B | 3B | 2.83B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 3.88B | 4.02B | 4.05B |
| Tangible Assets (Net) | -4.92B | -3.69B | -4.37B |
| Other Assets | 0.94B | 1.22B | 1.17B |
| Total Assets | 23.65B | 23.07B | 21.76B |
| Accounts Payable | 395.50M | 298.70M | 330.30M |
| Other Current Liabilities | 2.90B | 2.46B | 2.44B |
| Total Current Liabilities | 3.37B | 3.45B | 3.38B |
| Total Liabilities | 11.05B | 10.22B | 10.19B |
| Long Term Debt | 5.94B | 5.94B | 5.95B |
| Current Long Term Debt | 3.20M | 573.20M | 559.90M |
| Minority Interest | 131.10M | 0 | 0 |
| Common Stock | 211.50M | 211.48M | 211.43M |
| Treasury Stock | 2.98B | 2.98B | 2.98B |
| Retained Earnings | 15.81B | 16.11B | 14.88B |
| Capital Surplus | 97.80M | 59.20M | 19.30M |
| Shareholder Equity | 12.61B | 12.86B | 11.59B |
| Other Liabilities | N.A | N.A | N.A |
Biogen Inc. cash flow (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | |
|---|---|---|---|---|
| Net Income | 701.50M | 701.50M | 1.54B | 1.40B |
| Depreciation | 366.80M | 114.70M | 112.90M | 119.90M |
| Changes in Receivables | -22.6M | 22.60M | 29.50M | -133.5M |
| Changes in Inventories | 75M | -82.4M | -126M | -62.2M |
| Cash Change | -747.8M | -160.1M | -206.4M | -322.4M |
| Cash Flow | 4.60B | 1.18B | 1.95B | 1.47B |
| Capital Expenditures | -338.8M | -84.1M | -105M | -261.7M |
| Investments | N.A | 41.90M | -720.4M | 705.10M |
| Investing Activity (other) | N.A | -10.2M | -7.3M | -500K |
| Total Investing Cash Flows | -442.2M | -52.4M | -832.7M | 442.90M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | 3.16B | N.A | 1.47B | N.A |
| Other Financing Cash Flows | N.A | -70.3M | 17.80M | 4.50M |
| Cash Flow Financing | -4.87B | -1.31B | -1.31B | -2.25B |
| Exchange Rate Effect | N.A | 24.10M | -8.8M | 12.70M |
Biogen Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | 1.44B | 1.55B | 1.49B | 1.41B |
| Depreciation | -103M | 329.50M | 117M | 121.10M |
| Changes in Receivables | 45.10M | 1.30M | 98.90M | -130.6M |
| Changes in Inventories | -66.5M | -61.4M | -20.3M | 129M |
| Cash Change | 569.80M | 620.50M | -520.6M | 1.02B |
| Cash Flow | 1.96B | 1.69B | 1.96B | 1.46B |
| Capital Expenditures | -265.4M | -90.1M | -186.9M | -127.1M |
| Investments | 0.94B | -1.2B | 826.20M | 664.20M |
| Investing Activity (other) | 4.60M | -600K | -4M | -300M |
| Total Investing Cash Flows | 708.40M | -365.9M | -110.8M | 238.80M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | -40.2M | 22.20M | 17.20M | 8.70M |
| Cash Flow Financing | -2.12B | -689M | -2.38B | -679.3M |
| Exchange Rate Effect | 17.60M | -19.5M | 1.90M | 400K |
Biogen Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | 0.95B | 1.44B | 866.60M | 1.17B |
| Depreciation | 153M | 157.20M | 171.50M | 168.90M |
| Changes in Receivables | 40.30M | -92.8M | 59.80M | -173.1M |
| Changes in Inventories | -20.2M | 8.20M | -42.7M | 2.60M |
| Cash Change | -1.16B | 1.14B | -2.86B | 2.53B |
| Cash Flow | 1.90B | 1.74B | 1.10B | 1.46B |
| Capital Expenditures | -225.9M | -190.7M | -264.8M | -204.7M |
| Investments | -1.56B | -127.5M | -121.3M | 2.15B |
| Investing Activity (other) | 162.90M | -299.2M | -763.7M | -600M |
| Total Investing Cash Flows | -1.63B | -619.1M | -1.15B | 1.35B |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | -3.2M | N.A |
| Other Financing Cash Flows | -84.4M | 25.10M | -38.3M | -18.6M |
| Cash Flow Financing | -1.44B | 25.10M | -2.79B | -268.6M |
| Exchange Rate Effect | 4.80M | -5.4M | -17.1M | -0.9M |
Biogen Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -297.4M | 1.23B | 862.80M |
| Depreciation | 177.80M | 177.40M | 182.60M |
| Changes in Receivables | -234.1M | 47.60M | -307.1M |
| Changes in Inventories | 75.80M | -85M | -39.1M |
| Cash Change | 25.70M | 378.60M | 245.50M |
| Cash Flow | 1.52B | 1.63B | 1.17B |
| Capital Expenditures | -175.6M | -279.2M | -322.8M |
| Investments | -168M | -669.8M | 420.90M |
| Investing Activity (other) | -425.9M | -297.8M | -300.7M |
| Total Investing Cash Flows | -769.5M | -1.25B | -202.6M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | -557.7M | -3.2M | N.A |
| Other Financing Cash Flows | -150.4M | -16.3M | 30.80M |
| Cash Flow Financing | -708.1M | -19.5M | -751M |
| Exchange Rate Effect | -15M | 16.60M | 29.90M |
Biogen Inc. dividends (USD)
Insider Roster
| Entity name | Report date | Shares held |
|---|---|---|
| MCDONNELL MICHAEL R | 03-09-2020 | 16,090 |
| PANGIA ROBERT W | 05-06-2020 | 20,632 |
| Rowinsky Eric K | 05-06-2020 | 17,069 |
| SHERWIN STEPHEN A | 05-06-2020 | 16,328 |
| LEAMING NANCY | 05-06-2020 | 12,988 |
| Mulligan Richard | 05-06-2020 | 12,954 |
| DORSA CAROLINE | 05-06-2020 | 21,097 |
| DENNER ALEXANDER J | 05-06-2020 | 12,954 |
Insider Summary
| Full name | Reported title | Total bought | Total sold | Net transacted |
|---|---|---|---|---|
| Mulligan Richard | 1,780 | 0 | 1,780 |
Insider Transactions
| Full name | Reported title | Effective date | Amount of shares | Price per share | Total cost |
|---|---|---|---|---|---|
| MCDONNELL MICHAEL R | EVP, Chief Financial Officer | 01-09-2020 | +16,090 | N.A | N.A |
| Gregory Ginger | EVP, Human Resources | 31-07-2020 | +212 | N.A | N.A |
| Kramer Robin | VP, Chief Accounting Officer | 01-07-2020 | +755 | N.A | N.A |
| DORSA CAROLINE | N.A | 03-06-2020 | +890 | N.A | N.A |
| PANGIA ROBERT W | N.A | 03-06-2020 | +890 | N.A | N.A |
| HAWKINS WILLIAM A | N.A | 03-06-2020 | +890 | N.A | N.A |
| SHERWIN STEPHEN A | N.A | 03-06-2020 | +890 | N.A | N.A |
| LEAMING NANCY | N.A | 03-06-2020 | +890 | N.A | N.A |
| PAPADOPOULOS STELIOS | N.A | 03-06-2020 | +1,470 | N.A | N.A |
| Posner Brian S | N.A | 03-06-2020 | +890 | N.A | N.A |
| Mulligan Richard | N.A | 03-06-2020 | +890 | N.A | N.A |
| SHERWIN STEPHEN A | N.A | 11-03-2020 | +1,355 | N.A | N.A |
| Robin C. Kramer | VP, Chief Accounting Officer | 03-12-2019 | -84 | N.A | N.A |
| Robin C. Kramer | VP, Chief Accounting Officer | 03-12-2019 | -25 | 290.70 | 7,267.50 |
| Robin C. Kramer | VP, Chief Accounting Officer | 03-12-2019 | -92 | N.A | N.A |
| Robin C. Kramer | VP, Chief Accounting Officer | 03-12-2019 | +84 | N.A | N.A |
| Brian S. Posner | Director | 02-12-2019 | -1,055 | 292.35 | 308,429.25 |
| Chirfi Guindo | EVP Glob. Prod Strat and Comm | 01-12-2019 | -625 | N.A | N.A |
| Chirfi Guindo | EVP Glob. Prod Strat and Comm | 01-12-2019 | -231 | 299.81 | 69,256.11 |
| Chirfi Guindo | EVP Glob. Prod Strat and Comm | 01-12-2019 | +543 | N.A | N.A |
| Chirfi Guindo | EVP Glob. Prod Strat and Comm | 01-12-2019 | -160 | 299.81 | 47,969.60 |
| Chirfi Guindo | EVP Glob. Prod Strat and Comm | 01-12-2019 | -543 | N.A | N.A |
| Stephen A. Sherwin | Director | 04-11-2019 | -325 | N.A | N.A |
| Stephen A. Sherwin | Director | 04-11-2019 | -200 | N.A | N.A |
| Stephen A. Sherwin | Director | 04-11-2019 | -200 | N.A | N.A |
| Ginger Gregory | EVP, Human Resources | 01-08-2019 | -80 | 243.06 | 19,444.80 |
| Ginger Gregory | EVP, Human Resources | 01-08-2019 | -247 | N.A | N.A |
| Ginger Gregory | EVP, Human Resources | 01-08-2019 | -179 | N.A | N.A |
| Ginger Gregory | EVP, Human Resources | 01-08-2019 | +179 | N.A | N.A |
| Ginger Gregory | EVP, Human Resources | 01-08-2019 | -128 | 243.06 | 31,111.68 |
| Daniel Karp | EVP, Corporate Development | 02-07-2019 | +196 | N.A | N.A |
| Daniel Karp | EVP, Corporate Development | 02-07-2019 | -390 | N.A | N.A |
| Daniel Karp | EVP, Corporate Development | 02-07-2019 | -196 | N.A | N.A |
| Daniel Karp | EVP, Corporate Development | 02-07-2019 | -58 | 236.37 | 13,709.46 |
| Caroline D. Dorsa | Director | 19-06-2019 | +1,155 | N.A | N.A |
| Eric K. Rowinsky | Director | 19-06-2019 | +1,155 | N.A | N.A |
| Robert W. Pangia | Director | 19-06-2019 | +1,155 | N.A | N.A |
| Lynn Schenk | Director | 19-06-2019 | +1,155 | N.A | N.A |
| Stelios B. Papadopoulos | Director | 19-06-2019 | +1,905 | N.A | N.A |
| Brian S. Posner | Director | 19-06-2019 | +1,155 | N.A | N.A |
| Alexander John Denner | Director | 19-06-2019 | +1,155 | N.A | N.A |
| Richard Charles Mulligan | Director | 19-06-2019 | +1,155 | N.A | N.A |
| Jesus B. Mantas | Director | 19-06-2019 | +1,155 | N.A | N.A |
| Stephen A. Sherwin | Director | 19-06-2019 | +1,155 | N.A | N.A |
| William A. Hawkins | Director | 19-06-2019 | +1,155 | N.A | N.A |
| Nancy L. Leaming | Director | 19-06-2019 | +1,155 | N.A | N.A |
| EVP, Research and Development | 01-06-2019 | -1,126 | N.A | N.A | |
| EVP, Research and Development | 01-06-2019 | -460 | 219.29 | 100,873.40 | |
| EVP, Research and Development | 01-06-2019 | +1,126 | N.A | N.A | |
| EVP, Research and Development | 01-06-2019 | -500 | 219.29 | 109,645.00 | |
| EVP, Research and Development | 01-06-2019 | -1,376 | N.A | N.A |